Spero Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
Mailing Address 675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
Phone 857-242-1600
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
$182.39M
Total Assets
$75.93M
Stockholders' Equity
$76.33M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | September 3, 2025 | View on SEC |
Insider Trading
SELL 2 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.